All In Biotech

Drug Trial Radar · NCT01215851

Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) (NC-001)

A Phase II Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of the Following: TMC207 Alone, TMC207 Plus Pyrazinamide,TMC207 Plus PA-824,PA-824 Plus Pyrazinamide and PA-824 Plus Pyrazinamide and Moxifloxacin, in Adult Patients With Newly Diagnosed, Smear-Positive Pulmonary Tuberculosis.

Last checked: Nov 19, 2026Latest source record: Feb 28, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

85

Actual

Start

Oct 2010

Primary completion

May 2011

Study completion Aug 2011

Sponsor

Lead sponsor
Global Alliance for TB Drug DevelopmentAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 7, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The trial will evaluate the extended bactericidal activity of 14 consecutive days of oral administration of TMC207 alone, TMC207 with pyrazinamide, TMC207 with PA-824, PA-824 with pyrazinamide and PA-824 with moxifloxacin and pyrazinamide, as determined by the rate of change of log CFU in sputum over the time period Day 0-14 in participants with smear positive pulmonary tuberculosis (TB). A control group will receive standard treatment.

Conditions

  • Pulmonary Tuberculosis

Interventions

  • PA-824Drug

    200 mg tablet, once daily for 14 days

  • PyrazinamideDrug

    Dosed by Weight

  • TMC207Drug

    TMC207 700 mg Day 1; 500mg Day 2; 400mg Days 3-14

  • RifafourDrug

    Rifafour e-275

  • MoxifloxacinDrug

    moxifloxacin 400 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Early Bactericidal Activity (EBA) Measured as the Mean Rate of Change of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time (Days 0-14).Time frame: 14 consecutive days of treatment

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Centre for Tuberculosis Research Innovation, UCT Lung Institute

    Cape Town, South Africa

  • Task Applied Science, Karl Bremer Hospital

    Cape Town, South Africa

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.